Lupin launches generic epilepsy tablets in the US

Pharmaceutical major Lupin announced the launch of a generic equivalent of Lundbeck Pharms’ Onfi tablets in the US market.

Clobazam is used to control seizures in adults and children 2 years of age and older who have Lennox-Gastaut syndrome.

Lennox-Gastaut syndrome (LGS) or childhood epileptic encephalopathy is a pediatric epilepsy syndrome characterized by multiple seizure types, mental retardation and regression.

Clobazam tablets, in doses of 10 mg and 20 mg, had annual sales of $479 million in the US market.

Lupin received approval from the United States Food and Drug Administration for sales of Clobazam tablets on December 17, 2018.

Mumbai-based Lupin is one of the world’s biggest makers of generic drugs, and sells both branded and generic formulations, biotechnology products and pharmaceutical ingredients globally.

It is the world’s biggest manufacturer of anti-TB medicines and focuses on cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID segments of the pharma market.